Roots Analysis has announced the addition of “Global Antibiotics Market 2023–2035” report to its list of offerings.
Clinical trials have demonstrated the enormous benefits offered by novel antibiotics for the treatment of a wide range of infections, presenting lucrative opportunities for the players engaged in the development of these therapies. Driven by the extensive R&D efforts of both industry and non-industry players, along with the growing demand for effective antibiotic therapies, the market is anticipated to witness steady growth over the next decade.
To order this 175+ slides report, which features 210 figures and 195+ tables, please visit this Global Antibiotics Market
55% of the antibiotic generics have received approval between 1986-2000. Of these, majority (63%) of the generics have been approved for use in North America. It is worth highlighting that over 50% of the generics act via inhibition of bacterial cell wall synthesis.
Around 40% of the abovementioned therapeutics have been approved in the last five years (since 2019). Notably, more than 90% of the brands work against a broad spectrum of bacteria. Of these, more than 80% of the brands have been approved to be used as monotherapy.
Majority (~45%) of the aforementioned therapies are being evaluated in early stages of development (phase I and phase II). Of these, ~50 of the therapies is being evaluated to be administered intravenously. It is worth noting that more than 65% of the clinical-stage antibiotics belong to semi-synthetic nature of source.
Majority of the deals related to antibiotics were observed to be research and development agreements, representing 25% of the total partnerships inked in this industry. Further, most of the deals (intercontinental and intracontinental) have been inked by players based in North America.
The clinical activity (in terms of the number of trials registered) has increased at a CAGR of ~25%, during the period 2010-2022. Of the total number of trials, 75% of the trials have been completed. Further, among the active trials, more than 65% of the trials are currently recruiting patients.
The proprietary framework evaluates latest approved antibiotic brands, based on parameters such as dosing frequency, drug efficacy, geographical reach, innovation features, inter-class competition, market landscape competition, prevalence of target disease indication, price of antibiotic, route of administration, spectrum of activity, type of target bacteria, and type of therapy.
Majority (77%) of the current market share is expected to be captured by generic antibiotics, while branded antibiotics hold a 23% share of the overall market. North America and Europe are anticipated to capture significant market share by 2035.
To request a sample copy / brochure of this report, please visit this Antibiotics Market Sample Report
The financial opportunity within the global antibiotics market has been analysed across the following segments:
The research includes profiles of the key players engaged in the development of approved antibiotics (listed below); each profile features a brief overview of the company overview, key executives, financial information, details related to its antibiotics portfolio, recent developments and an informed future outlook, key strategies, key focus areas and expert opinions
For additional details, please visit https://www.rootsanalysis.com/reports/global-antibiotics-market.html or email sales@rootsanalysis.com
Contact:
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Gaurav.chaudhary@rootsanalysis.com
MEDIA CITATIONS
We are your partners with no equity
We fit in your budget
We love what we do
Chance to prove ourselves
Best in class quality of work
Most trusted consulting partner in the industry
SUBSCRIBE TO INDUSTRY UPDATES
.png)
